Difference between revisions of "Sorafenib (Nexavar)"

Revision as of 07:26, 4 May 2017

General information

Class/mechanism: Tyrosine kinase inhibitor that inhibits multiple kinases: CRAF, BRAF, KIT, FLT-3, RET, vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor beta (PDGFR-B). Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.^[1]^[2]^[3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

12/20/2005: FDA approved "for the treatment of patients with advanced renal cell carcinoma (RCC)."
11/16/2007: FDA approved "for the treatment of patients with unresectable hepatocellular carcinoma (HCC)."
11/22/2013: FDA approved "for the treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment"

Also known as

BAY 43-9006, BAY 54-9085, Sorafenib Tosilate

References

[insert-1] 1.0 ^1.1 ^1.2 Sorafenib (Nexavar) package insert

[2] Sorafenib (Nexavar) package insert (locally hosted backup)

[3] Nexavar manufacturer's website

[4] Sorafenib (Nexavar) patient drug information (Chemocare)

[5] Sorafenib (Nexavar) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

[5]

@@ Line 1: / Line 1: @@
 ==General information==
-Class/mechanism: Tyrosine kinase inhibitor that inhibits multiple kinases: CRAF, BRAF, KIT, FLT-3, RET, vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor beta (PDGFR-B).  Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.<ref name="insert">[http://berlex.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf Sorafenib (Nexavar) package insert]</ref><ref>[[Media:Sorafenib.pdf | Sorafenib (Nexavar) package insert (locally hosted backup)]]</ref><ref>[http://www.nexavar.com Nexavar manufacturer's website]</ref>
+Class/mechanism: Tyrosine kinase inhibitor that inhibits multiple kinases: CRAF, BRAF, KIT, FLT-3, RET, vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor beta (PDGFR-B).  Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.<ref name="insert">[http://labeling.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf Sorafenib (Nexavar) package insert]</ref><ref>[[Media:Sorafenib.pdf | Sorafenib (Nexavar) package insert (locally hosted backup)]]</ref><ref>[http://www.nexavar.com Nexavar manufacturer's website]</ref>
 <br>Route: PO
 <br>Extravasation: n/a
@@ Line 15: / Line 15: @@
 ==Patient drug information==
-*[http://berlex.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf#page=26 Sorafenib (Nexavar) package insert PDF pages 26-30]<ref name="insert"></ref>
+*[http://labeling.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf Sorafenib (Nexavar) package insert]<ref name="insert"></ref>
 *[http://www.chemocare.com/chemotherapy/drug-info/Sorafenib.aspx Sorafenib (Nexavar) patient drug information (Chemocare)]<ref>[http://www.chemocare.com/chemotherapy/drug-info/Sorafenib.aspx Sorafenib (Nexavar) patient drug information (Chemocare)]</ref>
 *[http://www.uptodate.com/contents/sorafenib-patient-drug-information Sorafenib (Nexavar) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/sorafenib-patient-drug-information Sorafenib (Nexavar) patient drug information (UpToDate)]</ref>